Form 4: Forbion Funds Reduce Stake in NewAmsterdam Pharma Through Multiple Share Sales

Forbion Capital funds have sold a portion of their NewAmsterdam Pharma holdings through a pre-arranged trading plan, reducing their overall stake.

Summary

• ForGrowth NAP B.V., along with related Forbion Capital funds, executed multiple sales of NewAmsterdam Pharma ordinary shares.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.
• The sales occurred on December 12th and 13th, 2024, at weighted average prices ranging from $25.0106 to $26.1763 per share.
• The total number of shares sold was 191,762.
• The sales were made on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. and Forbion Capital Fund IV Cooperatief U.A.
• Following these transactions, ForGrowth NAP B.V. still beneficially owns a significant number of NewAmsterdam Pharma shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, which is neither particularly positive nor negative. The sales do reduce the stake of a major shareholder, which could be seen as slightly negative.

Negatives

• The sales by Forbion funds indicate a reduction in their stake in NewAmsterdam Pharma.
• The sales were executed at prices between $25.00 and $26.405, which may be seen as a negative signal by some investors.

Risks

• Continued sales by Forbion funds could put downward pressure on the share price.
• The market may interpret these sales as a lack of confidence in the company's future prospects.

Industry Context

This filing reflects routine trading activity by a major shareholder and is not unusual in the biotech industry where venture capital funds often manage their positions over time.

Comparison to Industry Standards

• Similar sales by venture capital funds are common in the biotech sector as funds manage their portfolios and return capital to investors.
• Other companies with similar venture capital backing, such as Alnylam Pharmaceuticals and Moderna, have also seen similar share sales by their major shareholders.
• The trading plan mechanism is a standard practice to avoid insider trading concerns.

Stakeholder Impact

• The share sales may cause some short-term volatility in the stock price.
• Shareholders may interpret the sales as a lack of confidence from a major investor.

Key Dates

Keywords

NewAmsterdam Pharma, Forbion Capital, Share Sale, Rule 10b5-1, ForGrowth NAP B.V., Trading Plan, SEC Form 4